Fischer Lars, Knebel Phillip, Schröder Steffen, Bruckner Thomas, Diener Markus K, Hennes Roland, Buhl Klaus, Schmied Bruno, Seiler Christoph M
Department of General, Visceral and Trauma Surgery, University of Heidelberg, Im Neuenheimer Feld 110, D-69120, Heidelberg, Germany.
Ann Surg Oncol. 2008 Apr;15(4):1124-9. doi: 10.1245/s10434-007-9783-z. Epub 2008 Jan 23.
The objective of this study was to analyze factors leading to explantation of totally implanted access ports (TIAPs) and to assess its occurrence and clinical relevance.
Of 438 patient consecutive patients with a port explantation, 385 were eligible for this retrospective cohort study. Reasons for explantation as well as demographic, clinical, and surgical characteristics were analyzed by univariate and multivariate models.
The diagnoses leading to TIAP implantation were hematological malignancies in 142 patients (36.8%), breast cancer in 103 patients (26.8%), gastrointestinal cancer in 76 patients (19.8%), nonmalignant diseases in 46 patients (11.9%), and other malignant diseases in 18 patients (4.7%). The reasons for TIAP explantation were infection in 178 patients (46.2%), end of treatment in 129 patients (33.5%), thrombosis in 44 patients (11.4%), TIAP dysfunction in 22 patients (5.7%), and other reasons in 12 patients (3.2%). At the time of TIAP explantation, 115 patients (29.9%) were receiving chemotherapy, and 49 patients (12.7%) were considered immunocompromised. In case of TIAP explantation due to infection, the median length of TIAP in situ time was 303.3 days, whereas the cumulative 10-day and 30-day explantation rates were 2.8% and 10.6%, respectively. By multivariate models, TIAP explantation due to infection is statistically significantly decreased in patients with breast cancer (P < .01) but significantly increased in patients with recurrent TIAP implantation and with ongoing chemotherapy (P < .01).
TIAP explantations are caused primarily by late-term complications, mainly infections. The subsequent interruption of ongoing treatment makes further efforts necessary to reduce such complications.
本研究的目的是分析导致完全植入式输液港(TIAPs)取出的因素,并评估其发生率及临床相关性。
在438例连续进行输液港取出术的患者中,385例符合本回顾性队列研究的条件。通过单因素和多因素模型分析取出原因以及人口统计学、临床和手术特征。
导致植入TIAP的诊断情况为:血液系统恶性肿瘤142例(36.8%),乳腺癌103例(26.8%),胃肠道癌76例(19.8%),非恶性疾病46例(11.9%),其他恶性疾病18例(4.7%)。TIAP取出原因如下:感染178例(46.2%),治疗结束129例(33.5%),血栓形成44例(11.4%),TIAP功能障碍22例(5.7%),其他原因12例(3.2%)。在TIAP取出时,115例患者(29.9%)正在接受化疗,且49例患者(12.7%)被认为免疫功能低下。因感染导致TIAP取出时,TIAP在位时间的中位数为303.3天,而10天和30天的累积取出率分别为2.8%和10.6%。多因素模型显示,乳腺癌患者因感染导致的TIAP取出在统计学上显著减少(P <.01),但在TIAP重复植入和正在接受化疗的患者中显著增加(P <.01)。
TIAP取出主要由晚期并发症引起,主要是感染。后续正在进行的治疗中断使得有必要进一步努力减少此类并发症。